A citation-based method for searching scientific literature

Wassim Abida, Joshua Armenia, Anuradha Gopalan, Ryan Brennan, Michael Walsh, David Barron, Daniel Danila, Dana Rathkopf, Michael Morris, Susan Slovin, Brigit McLaughlin, Kristen Curtis, David M Hyman, Jeremy C Durack, Stephen B Solomon, Maria E Arcila, Ahmet Zehir, Aijazuddin Syed, Jianjiong Gao, Debyani Chakravarty, Hebert Alberto Vargas, Mark E Robson, Vijai Joseph, Kenneth Offit, Mark T A Donoghue, Adam A Abeshouse, Ritika Kundra, Zachary J Heins, Alexander V Penson, Christopher Harris, Barry S Taylor, Marc Ladanyi, Diana Mandelker, Liying Zhang, Victor E Reuter, Philip W Kantoff, David B Solit, Michael F Berger, Charles L Sawyers, Nikolaus Schultz, Howard I Scher. JCO Precis Oncol 2017
Times Cited: 188







List of co-cited articles
779 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
55

Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Marcin Cieslik, Matteo Benelli, Dan Robinson, Eliezer M Van Allen,[...]. Proc Natl Acad Sci U S A 2019
380
41

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
517
41


Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Colin C Pritchard, Joaquin Mateo, Michael F Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind Eeles,[...]. N Engl J Med 2016
772
37

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
32

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
232
26

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog,[...]. J Clin Oncol 2020
157
25

The long tail of oncogenic drivers in prostate cancer.
Joshua Armenia, Stephanie A M Wankowicz, David Liu, Jianjiong Gao, Ritika Kundra, Ed Reznik, Walid K Chatila, Debyani Chakravarty, G Celine Han, Ilsa Coleman,[...]. Nat Genet 2018
364
23

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
139
23

Genomics of lethal prostate cancer at diagnosis and castration resistance.
Joaquin Mateo, George Seed, Claudia Bertan, Pasquale Rescigno, David Dolling, Ines Figueiredo, Susana Miranda, Daniel Nava Rodrigues, Bora Gurel, Matthew Clarke,[...]. J Clin Invest 2020
81
27

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Ian D Davis, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath,[...]. N Engl J Med 2019
464
20

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Elena Castro, Chee Goh, David Olmos, Ed Saunders, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Nadiya Mahmud, Tokhir Dadaev, Koveela Govindasami, Michelle Guy,[...]. J Clin Oncol 2013
415
20

The mutational landscape of lethal castration-resistant prostate cancer.
Catherine S Grasso, Yi-Mi Wu, Dan R Robinson, Xuhong Cao, Saravana M Dhanasekaran, Amjad P Khan, Michael J Quist, Xiaojun Jing, Robert J Lonigro, J Chad Brenner,[...]. Nature 2012
20

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Elena Castro, Nuria Romero-Laorden, Angela Del Pozo, Rebeca Lozano, Ana Medina, Javier Puente, Josep Maria Piulats, David Lorente, Maria Isabel Saez, Rafael Morales-Barrera,[...]. J Clin Oncol 2019
136
19

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. N Engl J Med 2017
992
18

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
18

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Konrad H Stopsack, Subhiksha Nandakumar, Andreas G Wibmer, Samuel Haywood, Emily S Weg, Ethan S Barnett, Chloe J Kim, Emily A Carbone, Samantha E Vasselman, Bastien Nguyen,[...]. Clin Cancer Res 2020
40
45

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor,[...]. N Engl J Med 2014
17

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Wassim Abida, David Campbell, Akash Patnaik, Jeremy D Shapiro, Brieuc Sautois, Nicholas J Vogelzang, Eric G Voog, Alan H Bryce, Ray McDermott, Francesco Ricci,[...]. Clin Cancer Res 2020
133
17

Integrative genomic profiling of human prostate cancer.
Barry S Taylor, Nikolaus Schultz, Haley Hieronymus, Anuradha Gopalan, Yonghong Xiao, Brett S Carver, Vivek K Arora, Poorvi Kaushik, Ethan Cerami, Boris Reva,[...]. Cancer Cell 2010
17

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J Eigl, Daygen Finch,[...]. Cancer Discov 2018
238
16

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Wassim Abida, Michael L Cheng, Joshua Armenia, Sumit Middha, Karen A Autio, Hebert Alberto Vargas, Dana Rathkopf, Michael J Morris, Daniel C Danila, Susan F Slovin,[...]. JAMA Oncol 2019
244
16

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Kim N Chi, Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Robert Given, Álvaro Juárez Soto, Axel S Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura,[...]. N Engl J Med 2019
433
16

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Christopher E Barbieri, Sylvan C Baca, Michael S Lawrence, Francesca Demichelis, Mirjam Blattner, Jean-Philippe Theurillat, Thomas A White, Petar Stojanov, Eliezer Van Allen, Nicolas Stransky,[...]. Nat Genet 2012
16

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko,[...]. J Clin Oncol 2020
215
16

Genomic hallmarks of localized, non-indolent prostate cancer.
Michael Fraser, Veronica Y Sabelnykova, Takafumi N Yamaguchi, Lawrence E Heisler, Julie Livingstone, Vincent Huang, Yu-Jia Shiah, Fouad Yousif, Xihui Lin, Andre P Masella,[...]. Nature 2017
307
15

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Ronald de Wit, Johann de Bono, Cora N Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles,[...]. N Engl J Med 2019
206
15

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Anis A Hamid, Kathryn P Gray, Grace Shaw, Laura E MacConaill, Carolyn Evan, Brandon Bernard, Massimo Loda, Niall M Corcoran, Eliezer M Van Allen, Atish D Choudhury,[...]. Eur Urol 2019
87
17

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Alastair W S Ritchie, Claire L Amos, Clare Gilson, Rob J Jones,[...]. N Engl J Med 2017
842
14

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard,[...]. Lancet 2016
14

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
660
14

Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
14

CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Victor Sacristan Santos, Benjamin L Maughan, Roberto Pili, Nabil Adra, Cora N Sternberg,[...]. JCO Precis Oncol 2020
70
20

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Eugenia Giannopoulou, Balabhadrapatruni V S K Chakravarthi, Sooryanarayana Varambally,[...]. Nat Med 2016
751
13

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
13

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
12

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P Hoyle, Adnan Ali, Alastair W S Ritchie, Gerhardt Attard, Simon Chowdhury, William Cross,[...]. Lancet 2018
523
12

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Yi-Mi Wu, Marcin Cieślik, Robert J Lonigro, Pankaj Vats, Melissa A Reimers, Xuhong Cao, Yu Ning, Lisha Wang, Lakshmi P Kunju, Navonil de Sarkar,[...]. Cell 2018
254
12

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Fatima Karzai, David VanderWeele, Ravi A Madan, Helen Owens, Lisa M Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L Beshiri,[...]. J Immunother Cancer 2018
128
12

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Alexander W Wyatt, Matti Annala, Rahul Aggarwal, Kevin Beja, Felix Feng, Jack Youngren, Adam Foye, Paul Lloyd, Matti Nykter, Tomasz M Beer,[...]. J Natl Cancer Inst 2017
175
12

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Ping Mu, Zeda Zhang, Matteo Benelli, Wouter R Karthaus, Elizabeth Hoover, Chi-Chao Chen, John Wongvipat, Sheng-Yu Ku, Dong Gao, Zhen Cao,[...]. Science 2017
468
11

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel Clarke, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem, Aude Fléchon, Charles Redfern,[...]. Lancet Oncol 2018
161
11

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
Sheng Yu Ku, Spencer Rosario, Yanqing Wang, Ping Mu, Mukund Seshadri, Zachary W Goodrich, Maxwell M Goodrich, David P Labbé, Eduardo Cortes Gomez, Jianmin Wang,[...]. Science 2017
469
11

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
11

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
11

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D Shore,[...]. J Clin Oncol 2019
281
11

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, Glenn Liu, David F Jarrard, Noah M Hahn, Daniel H Shevrin, Robert Dreicer, Maha Hussain, Mario Eisenberger,[...]. J Clin Oncol 2018
344
11

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
11

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Gillian Vandekerkhove, Werner J Struss, Matti Annala, Heini M L Kallio, Daniel Khalaf, Evan W Warner, Cameron Herberts, Elie Ritch, Kevin Beja, Yulia Loktionova,[...]. Eur Urol 2019
76
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.